Innovent Biologics (HKG:1801) said second-quarter product revenue exceeded 4.3 billion yuan, up about 60% from a year earlier, according to a Wednesday Hong Kong bourse filing.

First-half product revenue topped 8.2 billion yuan, representing year-over-year growth of more than 55%.

The growth was driven by strong sales of flagship products, including mazdutide, as well as broader market penetration of its tyrosine kinase inhibitor therapies included in China's National Reimbursement Drug List.